Literature DB >> 32010593

Cancer stem-neuroendocrine cells in an atypical carcinoid case report.

Valentina Masciale1, Giulia Grisendi2, Federico Banchelli3, Roberto D'Amico3, Antonino Maiorana4, Uliano Morandi1, Massimo Dominici2, Beatrice Aramini1.   

Abstract

Lung neuroendocrine cells tumor (NET) classification and diagnosis, particularly for typical and atypical carcinoids, are complicated by a variable natural history and nonspecific symptoms. Mechanisms for the development and progression of well-differentiated lung NETs are still unclear. An accurate and timely diagnosis can ensure the implementation of appropriate treatment and impact on prognosis. One of the main unclear point is the definition of these cells' composition. In fact, it is known that carcinoids are mainly constituted by neuroendocrine cells. Aim of our report is to show for the first time the presence of a high percentage of cancer stem cells (CSCs) in an atypical carcinoid. The ALDEFLUOR assay was used to identify and sort ALDHhigh and ALDHlow human lung cancer cells following tissue digestion. SOX2 was additionally determined by immunohistochemistry. All specimens contained the 53.10% of ALDHhigh cells among all viable lung cancer cells, which indicates that more than half of the entire tumor cell population was composed by CSCs. As expected also in immunohistochemistry, about a half of the nuclei of the cells were positive for SOX2. We strongly support the hypothesis of the presence of cancer stem-neuroendocrine cells (CSCs-NETs) as subpopulation in these types of tumors. 2019 Translational Lung Cancer Research. All rights reserved.

Entities:  

Keywords:  Cancer stem cells (CSCs); atypical carcinoid; carcinoid tumors (TCs); case report; neuroendocrine cells tumor (NETs)

Year:  2019        PMID: 32010593      PMCID: PMC6976366          DOI: 10.21037/tlcr.2019.12.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  14 in total

1.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.

Authors:  David W Clark; Komaraiah Palle
Journal:  Ann Transl Med       Date:  2016-12

Review 2.  ALDH as a Stem Cell Marker in Solid Tumors.

Authors:  Mariel E Toledo-Guzmán; Miguel Ibañez Hernández; Ángel A Gómez-Gallegos; Elizabeth Ortiz-Sánchez
Journal:  Curr Stem Cell Res Ther       Date:  2019       Impact factor: 3.828

Review 3.  Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.

Authors:  Andrew E Hendifar; Alberto M Marchevsky; Richard Tuli
Journal:  J Thorac Oncol       Date:  2016-11-24       Impact factor: 15.609

Review 4.  Advanced typical and atypical carcinoid tumours of the lung: management recommendations.

Authors:  B Melosky
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

Review 5.  Classification of lung neuroendocrine tumors: lights and shadows.

Authors:  Marco Volante; Gaia Gatti; Mauro Papotti
Journal:  Endocrine       Date:  2015-03-21       Impact factor: 3.633

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 7.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 8.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Authors:  Bryan Oronsky; Patrick C Ma; Daniel Morgensztern; Corey A Carter
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

9.  Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.

Authors:  Xinwei Liu; Lihui Wang; Wei Cui; Xiangzhong Yuan; Lulu Lin; Qi Cao; Nannan Wang; Yi Li; Wei Guo; Xun Zhang; Chunfu Wu; Jingyu Yang
Journal:  Oncotarget       Date:  2016-09-06

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more
  2 in total

Review 1.  Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.

Authors:  Beatrice Aramini; Valentina Masciale; Giulia Grisendi; Federica Bertolini; Michela Maur; Giorgia Guaitoli; Isca Chrystel; Uliano Morandi; Franco Stella; Massimo Dominici; Khawaja Husnain Haider
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

2.  ALDH Expression in Angiosarcoma of the Lung: A Potential Marker of Aggressiveness?

Authors:  Beatrice Aramini; Valentina Masciale; Daniel Bianchi; Beatrice Manfredini; Federico Banchelli; Roberto D'Amico; Federica Bertolini; Massimo Dominici; Uliano Morandi; Antonino Maiorana
Journal:  Front Med (Lausanne)       Date:  2020-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.